Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review

Depression, or major depressive disorder (MDD), is a common and disabling condition affecting about 4.4% of the global population and characterised by depressed mood, anhedonia, fatigue, changes in sleep and appetite, executive deficits and suicidal ideation. Heuschkel and colleagues frame these symptoms as arising from interacting psychological and biological processes, and select six non‑exhaustive domains that are commonly impaired in MDD: mood, executive functioning, social skills, neuroplasticity, core neural networks, and neuroendocrine/neuroimmunological factors. The Introduction summarises evidence that MDD is associated with negative thinking patterns, excessive rumination and cognitive rigidity, fronto‑limbic and thalamo‑cortical network imbalances (including DMN hyperconnectivity and CEN/SN hypoconnectivity), reduced brain‑derived neurotrophic factor (BDNF) and HPA‑axis dysregulation with elevated cortisol and pro‑inflammatory cytokines.

The review searched literature between September 2018 and January 2019 using PubMed and Google Scholar. Separate search strings covered “depression” (including terms related to the six target domains), “mindfulness meditation” (and related interventions such as MBSR and MBCT) and “psilocybin” (the search also included other classical psychedelics where mechanistic overlap was relevant). Articles were included if they focused on psilocybin (or related classical psychedelics) and/or mindfulness and reported information relevant to the treatment of MDD; reference lists of included papers were also hand‑searched. The initial search returned 1,129 hits. After title and abstract screening 1,047 publications were excluded and 82 articles were retained for detailed analysis; a further 13 papers were added from reference lists, yielding a total of 95 included papers. The authors categorised each included article against one or more of the six depression‑related factors. Of the 95 papers, 67 described original experimental research, seven were original correlational studies, three were pooled data analyses, 12 were review papers, and the remaining six comprised theoretical pieces, editorials or a book. The Methods section does not report use of a formal systematic review protocol, risk‑of‑bias assessment, or meta‑analytic pooling; the approach is presented as a targeted, narrative comparison of mechanisms and findings across the six domains.

Heuschkel and colleagues report psychological and biological findings for mindfulness meditation (MM) and psilocybin across the six selected domains. Mood: MM has been associated with mood elevation in healthy samples and in clinical groups; for MBSR mood benefits were observed after short units of training (as little as three days) and persisted up to six months in some studies, while MBCT effects were reported up to three months. The proposed mechanism for MM is acquisition of mental strategies that reduce cognitive reactivity and rumination and promote emotional acceptance and non‑attachment. Psilocybin produced acute and sometimes persisting mood improvements in healthy volunteers, depressed and cancer patients after single or a few doses; reported dosing ranged from fixed 10 and 25 mg to weight‑adjusted regimens (approximately 1–30 mg/70 kg), and one study reported improvement up to 14 months after 0.2 mg/kg (≈14 mg/70 kg). Effects were dose‑related and frequently accompanied by mystical or peak experiences and an “afterglow” period. The authors note complementary mechanisms: MM works via top‑down, strategy‑based emotion regulation while psilocybin alters perceptual and cognitive content, potentially producing deep personal insights. Executive functioning: Repeated MM training was reported to improve cognitive flexibility, working memory, attention and inhibitory control, plausibly via reduced mind‑wandering and increased meta‑awareness. Psilocybin tended to acutely impair inhibition, attention and working memory and is commonly associated with subjective loss of control; at the same time it may increase cognitive flexibility and divergent thinking and bias cognition towards positive stimuli. Many of psilocybin’s acute cognitive effects are linked to 5‑HT2A receptor agonism. The authors highlight a potential complementary interaction—MM could buffer psilocybin‑related loss of control by strengthening executive control—but also caution that MM might interfere with therapeutic disinhibition produced by psychedelics. Social skills: MM has been linked to greater relationship satisfaction and the development of relational programmes (for example mindful relating, MBRE) that emphasise compassion and attentive communication. Psilocybin was reported to improve aspects of empathy and emotional face recognition, to reduce feelings of social exclusion, and to induce experiences of ego dissolution associated with increased connectedness and longer‑term increases in openness. The review suggests MM primarily affects interpersonal behaviour and social regulation, while psilocybin acts more on intrapersonal processes (empathy, self‑experiences), thus potentially producing complementary improvements in social functioning. Neuroplasticity: MM‑related increases in BDNF were reported mainly after prolonged practice rather than single sessions; putative mechanisms include frontal activation, vagal stimulation and reduced stress. Psilocybin and related psychedelics are hypothesised to promote rapid neuroplasticity via 5‑HT2A‑mediated glutamatergic cascades and associated increases in BDNF, with a single dose potentially inducing a transient but powerful plastic state. The authors contrast MM’s incremental, top‑down plasticity with psilocybin’s transient, bottom‑up plastic boost and suggest the two could mutually potentiate one another. Neural core networks: Mindfulness practice engages salience network regions (insula, anterior cingulate cortex) and over time increases dorsolateral PFC involvement and cortical thickness in insula, sensory cortices and PFC; it is associated with reduced amygdala volume. Psilocybin appears to reduce functional integrity within canonical networks (notably DMN disintegration) while increasing connectivity between networks, a pattern linked to ego dissolution and flexible cognition. The review discusses mixed imaging findings (for example reports of frontal hyperactivation versus decreased perfusion) and attributes some discrepancies to analytical approaches. A study administering 0.315 mg/kg psilocybin during a five‑day meditation retreat is noted: pre‑post resting‑state decoupling of medial prefrontal and posterior cingulate cortices related to ego dissolution and predicted positive psycho‑social changes at four months. Neuroendocrine and neuroimmune factors: MM generally reduced subjective stress, but effects on cortisol were inconsistent; eight weeks of MBSR had no effect on cortisol in some healthy samples yet reduced cortisol in cancer patients, and MBCT findings differed. MM may optimise HPA‑axis responsivity rather than uniformly lowering cortisol, and evidence on reductions in pro‑inflammatory cytokines such as IL‑6 is mixed. Psilocybin was associated with an acute cortisol increase and, in some clinical samples, reduced subjective stress for up to three months; 5‑HT2A agonism is theorised to have anti‑inflammatory effects based on studies of related psychedelics, though evidence specific to psilocybin remains limited and may be context‑dependent. The authors propose that MM and psilocybin may act complementarily on HPA and immune signalling, MM via progressive top‑down regulation and psilocybin via transient anti‑inflammatory and neuroendocrine modulation.

Heuschkel and colleagues interpret their synthesis as indicating that MM and psilocybin share beneficial effects on mood, social functioning and neuroplasticity, while differing on executive function, network organisation and neuroendocrine/neuroimmune markers. They emphasise that mood and neuroplasticity effects are dose‑ or practice‑dependent: more extensive MM practice or higher psilocybin doses tend to produce larger effects, and psilocybin can induce neuroplastic changes after a single administration whereas MM typically requires repeated training. From a psychological viewpoint, MM supplies enduring mental strategies that strengthen self‑regulation, while psilocybin induces transient neuromodulatory states and personal insights that may loosen maladaptive cognitive content; biologically, MM acts through repeated top‑down prefrontal and limbic adjustments whereas psilocybin produces widespread, bottom‑up network disintegration and putative anti‑inflammatory effects. The authors suggest these differing mechanisms could be complementary, for example MM practising before psilocybin might reduce acute adverse reactions and increase the likelihood or intensity of therapeutic peak experiences, and MM might help consolidate plastic state changes induced by psilocybin. For future clinical research the review recommends randomised, double‑blind, placebo‑controlled trials comparing psilocybin‑assisted mindfulness‑based interventions (MBI) with psilocybin alone, MM alone and conventional antidepressants (SSRIs). Proposed primary endpoints include standard depression scales (Hamilton, BDI) with daily diaries and repeated assessments; secondary measures encompass cognitive tests, self‑reports, functional and structural brain imaging, and biological markers such as BDNF, cortisol, oxytocin and cytokines. The authors favour an eight‑week MBI preceding a psilocybin session but acknowledge that optimal sequencing and dosing remain to be established. They also propose that mindfulness training for psychedelic therapists could be evaluated as a potential modifier of patient outcomes. Acknowledged limitations include heterogeneity in methods across MM studies (varied assessment instruments, populations and absence of active control groups), small sample sizes and open‑label designs in many psilocybin studies, conceptual variability in what constitutes MM (FAM, OMM, MBCT, MBSR, MBRE), and reliance in places on mechanistic hypotheses that are not yet empirically tested (for example specific immunomodulatory pathways and BDNF effects). The authors stress that these limitations constrain the strength of inferences and that empirical testing in rigorously controlled clinical trials is required to substantiate the theoretical complementarities described.

The review offers a theoretical synthesis suggesting that MM and psilocybin may be complementary or synergistic in treating depression, particularly with respect to mood, social functioning and neuroplasticity, and provides a rationale and roadmap for future clinical trials. Heuschkel and colleagues call for rigorous, well‑controlled studies in both healthy and clinical populations to evaluate psilocybin‑assisted mindfulness‑based interventions and to establish practical guidelines for implementation in clinical practice.